Purpose. Novel therapeutic regimens are needed to improve dismal outcomes associated with late-stage ovarian cancer. Oncolytic viruses are currently being tested in patients with ovarian cancer. Here we tested the therapeutic efficacy of combining doxorubicin with 34.5ENVE, an oncolytic herpes simplex virus transcriptionally driven by a modified stem cell-specific nestin promoter, and encoding for anti-angiogenic Vasculostatin-120 (VStat120) for use against progressive ovarian cancer. Experimental Design. Anti-tumor efficacy of 34.5ENVE was Ovarian cancer is the 5th most deadly cancer in women, and two-thirds of women present with disease that has already metastasized to abdominal organs. While many women show disease regression after standard therapy of carboplatin and/or paclitaxel, nearly 70% recur. Recurrent tumors are often resistant to first-line therapeutics which may be due to a reservoir of chemotherapy-resistant stem-like cells that survive therapy, and reinitiate aggressive tumor growth. Here we describe anti-tumor efficacy of oncolytic herpes simplex virus (oHSV) 34.5ENVE against nestin-positive ovarian cancer stem-like cells. Further, this study shows improved anti-tumor efficacy when 34.5ENVE is combined with doxorubicin both in vitro and in vivo. Doxorubicin-based therapies are frequently administered to patients with recurrent ovarian cancer, and this study underscores the significance of combining oHSV with doxorubicin for patients who have developed resistance to primary chemotherapy.
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Oncolytic viral (OV) therapy is a promising biological therapy that preferentially targets tumor cells for lytic destruction, while sparing normal cells (15, 16) . Many different OVs have been examined for use against ovarian cancer, including oncolytic herpes simplex virus (HSV)-1; adenovirus; reovirus; and measles virus. Here we examined therapeutic efficacy of 34.5ENVE (γ34.5-Expresed by Nestin promoter and Vasculostatin-120 Expressing) virus, an oncolytic HSV-1 that targets the transcription of the viral ICP34.5 gene to nestin-expressing cells, and encodes for Vasculostatin-120 (VStat120), a secreted antiangiogenic gene, for efficacy against ovarian cancer alone and in conjunction with doxorubicin (17) (18) (19) . Our results show significant anti-tumor efficacy of 34.5ENVE against disseminated peritoneal ovarian cancer in vivo.
Additionally, combination of 34.5ENVE with doxorubicin leads to synergistic killing of ovarian cancer cell lines and primary patient ascites-derived tumor cells in vitro. Treatment of mice bearing disseminated peritoneal ovarian cancer with a combination of doxorubicin and 34.5ENVE further improved antitumor efficacy. Future testing in patients will establish the potential for use of oncolytic HSV with doxorubicin for the treatment of progressive or disseminated ovarian cancer. 7 backbone using HSVQuik technology (24) . Revertant ENVE was created by removing the expression cassette containing the ICP34.5 and VStat120 gene by recombination. Viruses were propagated in Vero cells. Three days after infection, Vero cells and media were harvested and subjected to three cycles of freezing in liquid nitrogen and thawing at 37°C to liberate virions.
Cell debris was cleared by centrifugation (400g, 20 min at 4°C). Virus was pelleted from resultant supernatant by centrifugation at 13,000g for 1 hour. Virus titer was determined via plaque-forming assay in Vero cells, with plaque-forming units (PFU) assessed 3 days after infection (24) .
Cell Viability Assay and Chou-Talalay Analysis. Cancer cells were seeded into a 96-well plate (in 2% FBS media in 100µl volume), and were treated with vehicle or doxorubicin for 18 hours followed by drug wash out, and then virus infection. Three days after infection, cell viability was measured using a standard MTT assay (Roche Applied Sciences, Indianapolis IN).
For synergy analysis, dose response curves and 50% effective dose (ED50) values were determined for each individual treatment (drug or virus). Fixed ratios of ED50 of drug and/or virus were then used to treat the cells, either individually (as controls) or in combination.
CompuSyn software (ComboSyn, Inc. Paramus, NJ) program algorithm assessed the Combination Index (CI). Combined dose-response curves were fitted to Chou-Talalay lines, which are derived from the law of mass action. CI<1 indicates synergistic interaction, whereas CI>1 is antagonistic, and CI=1 is additive (25) (26) (27) (28) .
RT-PCR.
To measure relative nestin expression, RNA was purified from cell pellets (QIAgen RNeasy, Qiagen, Valencia, CA), per manufacturer's instructions. cDNA was generated Generation of concentrated conditioned media. To generate concentrated conditioned media, ovarian cancer cells were infected with the indicated oncolytic viruses (OV) at a multiplicity of infection (MOI) of 2 (two infectious viral particle per cell). One hour post-infection, unbound virus was washed away, and serum-free media was added. Twelve to 14 hours postinfection, conditioned media was harvested, treated with 0.4% human IgG to neutralize contaminating virus, and centrifuged for 1 hour at 13,000rpm to pellet any virus in the media prior to being concentrated 100-fold using 50,000 kDa Amicon Ultra centrifugal concentration filters (Millipore, Billerica, MA).
In Vitro Endothelial Cell Migration Assays. Endothelial cell migration assays were performed using a modified Boyden chamber assay similar to previous reports (17, 18) . Transwell membranes (8µM, Corning Costar, Cambridge, MA) were pre-coated on the underside with 5ug/mL fibronectin (Millipore, Billerica, MA) in PBS. Migration of serum-starved HDMEC towards conditioned medium was measured using transwell chambers. HDMEC were plated in the upper 9 chamber, and cells were allowed to migrate for twelve hours, at which point membranes were fixed in 1% glutaraldehyde and stained with 0.5% crystal violet; unmigrated cells were removed from top chamber (using cotton swab). Images of the membranes were obtained at 20x magnification, and quantified by counting 5 fields of view/well (n=3/group). The genetic structures of the oncolytic viral (OV) vectors used in this study have been previously described (17, 24, 36) , and are outlined in Figure 1A . Briefly, 34.5ENVE virus is an oncolytic HSV-1 with a disrupted ICP6 gene and deletions of both native copies of the ICP34.5 gene. It then has one copy of ICP34.5 driven by a modified nestin promoter reintroduced into the backbone, and also expresses antiangiogenic VStat120 driven by an immediate early viral promoter (called IE4/5)(17). A rescue virus, called revertant ENVE, was generated by removal of the inserted nestin-driven ICP34.5 and IE4/5-driven VStat120 expression cassette from the 34.5ENVE backbone. To determine if OvCa cell lines were sensitive to 34.5ENVE and revertant ENVE, the indicated cells were infected with virus at increasing multiplicity of infection (MOI), and cell viability was measured by standard MTT assay. Figure 1B shows sensitivity of OvCa cell lines to killing by both 34.5ENVE and revertant ENVE. The two-way ANOVA test indicated that in four out of six cell lines tested there is an overall significant difference between sensitivity to killing by revertant ENVE and 34.5ENVE ( Figure 1B ). The two cell lines, A2780CR and A2780CS, which only showed a trend towards overall significant difference, were also extremely sensitive to virus killing relative to the other four cell lines, even with the 34.5-deleted revertant ENVE. OvCa cell lines were also conducive to viral replication, with 34.5ENVE replicating better than revertant ENVE. Figure 1C shows viral replication after 72 hours in several cell lines as measured by standard plaque assay(24)(students t test; *, p<0.05, **, p<0.001; ***, p<0.0001). 
Viral
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To evaluate if increased sensitivity to OV correlated with nestin expression, we compared sensitivity of SKOV3 cells grown in vitro to SKOV3 cells harvested from murine ascites which develop in mice after tumor implantation. Tumor cells isolated from malignant ascites have been described to be more stem-cell like with higher nestin expression (6, 7) . Consistent with published reports, ex vivo SKOV3 cells harvested from ascites from three individual mice ( Figure 2A and B, "ascites-1", ascites-2" and "ascites-3") had more than a 10-fold increase in nestin expression compared to SKOV3 cells grown in vitro as determined by RT-PCR ( Figure   2A ). Along with increased nestin expression, the ex vivo ascites-derived tumor cells were significantly more sensitive overall killing by 34.5ENVE compared to revertant ENVE ( Figure 2B ; linear models were used to compare the means of two groups).
While SKOV3, A2780, and OVCAR3 cells were originally isolated from ovarian cancer patients, and are identified as such according to the ATCC, molecular profiling of commonly used ovarian cancer cells revealed some differences between the molecular profile of commonly-used ovarian cancer cell lines, and that of most high grade serous ovarian cancer tissue derived from patients(37). Thus we analyzed sensitivity of primary ovarian cancer patient ascites-derived tumor cells to 34.5ENVE or revertant ENVE. Ascites from ovarian cancer patients (de-identified patient numbers 140, 163, 179, 195; described in Supplementary Table 1) were isolated, and cultured as described in the Materials and Methods section. , . The ascites isolated tumor cell culture displayed cobblestone monolayer morphology as described (38) Figure 2D ; ANOVA models used to compare the mean of multiple groups; p value adjusted by Holm's procedure). Consistent with the increased nestin expression, the primary patient ascitesderived tumor cells also had increased overall sensitivity to 34.5ENVE-mediated killing compared to revertant ENVE ( Figure 2E ; linear models used to compare the means of two groups).
Antiangiogenic protein VStat120 is produced by 34.5ENVE after infection of OvCa, and reduces endothelial cell migration in vitro.
We examined the ability of OvCa cells infected with 34.5ENVE to produce and secrete VStat120 by Western blot analysis. Figure 3A untreated subcutaneous tumor. Gross histology of the ascites-free 34.5ENVE treated mice (6/8) revealed that they were free of disseminated intraperitoneal metastatic tumor seeding ( Figure   4D ; tumor nodules indicated with white asterisks).
Doxorubicin synergizes with 34.5ENVE to kill ovarian cancer cells in vitro and in vivo.
To evaluate impact of doxorubicin treatment in combination with 34.5ENVE, we determined what treatment schedule was most effective for combining the two agents. Briefly, SKOV3 cells were treated with a fixed concentration of doxorubicin (100nM) and with varying doses of 34.5ENVE administered 18 hours before doxorubicin, at the same time, or 18 hours after doxorubicin. Viability was measured 3 days after infection by MTT assay. Impact of doxorubicin and 34.5ENVE-on cytotoxicity is depicted in Figure 5A . Treatment with doxorubicin prior to 34.5ENVE (far right panel) showed an increase in cell killing compared to 34.5ENVE alone, thus all subsequent experiments were performed with this treatment schedule. Linear models were used to compare the means of two groups; p<0.001 comparing 34.5ENVE treatment to 34.5ENVE with doxorubicin.
We then measured sensitivity of doxorubicin-treated OvCa cell lines to 34.5ENVE. Cells were treated with doxorubicin for 18 hours followed by drug wash-out, and infected with 34.5ENVE for 72 hours. Viability was measured by MTT assay. Reduction in viability by either agent alone was quantified (D1: reduction in cell viability by doxorubicin; D2: reduction in cell viability by 
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doxorubicin to synergize with 34.5ENVE using the Chou-Talalay synergy analysis method as described (25, 26, 28, 39) . This analysis is frequently utilized to investigate synergy between anti-cancer killing of agents (39) (40) (41) . Briefly, the 50% effective dose (ED50) of doxorubicin and 34.5ENVE were each defined as the dosage yielding 50% cell viability, as compared to untreated controls. To evaluate if the combination resulted in synergistic cell killing, the cells were treated with doxorubicin, followed by drug wash-out, and then treated with 34.5ENVE. Figure 5C ). In a parallel experiment, we tested sensitivity of primary patient ascitesderived tumor cells to doxorubicin alone, and in combination with 34.5ENVE. Consistent with the cell line data, synergistic cell killing was observed between doxorubicin and 34.5ENVE in primary patient ascites-derived cell samples ( Figure 5D ). Research. Additionally, primary patient ascites-derived tumor cells displayed high levels of nestin gene expression, and were sensitive to 34.5ENVE-mediated oncolysis. This is the first study, to our 
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